J Oger

Latest

• Interferon beta and long-term disability in multiple sclerosis
• Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: A comparison of interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus sustained NAbs
• Multiple sclerosis in older adults: the clinical profile and impact of interferon beta treatment
• Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study
• Marginal structural Cox models for estimating the association between beta-interferon exposure and disease progression in a multiple sclerosis cohort
• Interferon beta and long-term disability in multiple sclerosis
• Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis